Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAS190792 in Asthma and COPD
NCT02059434Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LAS190792 in asthma and chronic obstructive pulmonary disease (COPD) (12 arms), sponsored by AstraZeneca. Primary endpoints: Subjects With ≥1 Treatment-emergent Adverse Event at 30 Days and Change From Baseline in Trough FEV1 at Day 2. Started Sep 2013; status: completed.
02
Drugs
LAS190792
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02059434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059434.